Hematopoietic stem cell transplantation in patients with chronic kidney disease

Seminars in Nephrology

Volumn 30, Issue 6, 2010, Pages 602-614

  Heher, Eliot C ^a   Spitzer, Thomas R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chronic kidney disease; Conditioning myeloma; Hematopoietic stem cell transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CALCINEURIN INHIBITOR; CEPHALOSPORIN DERIVATIVE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DRUG METABOLITE; FAMCICLOVIR; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MESNA; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VALACICLOVIR; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLADDER DISEASE; BONE MARROW DEPRESSION; BRADYCARDIA; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONTINUOUS RENAL REPLACEMENT THERAPY; DIALYSIS; DIARRHEA; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; FANCONI ANEMIA; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HLA TYPING; HUMAN; HYPONATREMIA; IMMUNE DEFICIENCY; INFECTION; KIDNEY TRANSPLANTATION; LEUKEMIA; LOW DRUG DOSE; LUNG TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MUCOSA INFLAMMATION; MUCOSAL DISEASE; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYELOABLATIVE CONDITIONING; MYELOMA; NEPHRECTOMY; NEPHROBLASTOMA; NEPHROTOXICITY; NEUROBLASTOMA; NONMYELOABLATIVE CONDITIONING; PATIENT SAFETY; PERICARDITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REDUCED INTENSITY CONDITIONING; SIBLING; SICKLE CELL ANEMIA; VIRUS INFECTION; WHOLE BODY RADIATION;

ANEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MORBIDITY; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; RENAL INSUFFICIENCY, CHRONIC;

EID: 78649953215     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.09.008     Document Type: Article

References (60)

1. Hahn T., Rondeau C., Shaukat A., et al. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 2003, 32:405-410.
2. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
3. Parimon T., Au D.H., Martin P.J., Chien J.W. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006, 144:407-414.
4. Thomas E., Storb R., Clift R.A., et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975, 292:832-843.
5. Thomas E.D., Storb R., Clift R.A., et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975, 292:895-902.
6. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
7. Storb R., Thomas E.D., Buckner C.D., et al. Allogeneic marrow grafting for treatment of aplastic anemia. Blood 1974, 43:157-180.
8. DeFronzo R.A., Braine H., Colvin M., Davis P.J. Water intoxication in man after cyclophosphamide therapy. Time course and relation to drug activation. Ann Intern Med 1973, 78:861-869.
9. Bramwell V., Calvert R.T., Edwards G., Scarffe H., Crowther D. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 1979, 3:253-259.
10. Haubitz M., Bohnenstengel F., Brunkhorst R., Schwab M., Hofmann U., Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002, 61:1495-1501.
11. Goldberg M.A., Antin J.H., Guinan E.C., Rappeport J.M. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986, 68:1114-1118.
12. Yamamoto R., Kanda Y., Matsuyama T., et al. Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure. Bone Marrow Transplant 2000, 26:685-688.
13. Gerrie A., Marsh J., Lipton J.H., Messner H., Gupta V. Marrow transplantation for severe aplastic anemia with significant renal impairment. Bone Marrow Transplant 2007, 39:311-313.
14. Sirohi B., Powles R., Kulkarni S., et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001, 85:325-332.
15. Samuels B.L., Bitran J.D. High-dose intravenous melphalan: a review. J Clin Oncol 1995, 13:1786-1799.
16. Carlson K., Hjorth M., Knudsen L.M. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure-a retrospective analysis and recommendations for dose adjustment. Br J Haematol 2005, 128:631-635. Nordic Myeloma Study Group.
17. Grazziutti M.L., Dong L., Miceli M.H., et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006, 38:501-506.
18. Badros A., Barlogie B., Siegel E., et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001, 114:822-829.
19. Rebibou J.M., Caillot D., Casasnovas R.O., et al. Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure. Bone Marrow Transplant 1997, 20:63-65.
20. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003, 101:1620-1629.
21. Lichtman S.M., Etcubanas E., Budman D.R., et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest 2002, 20:904-913.
22. Ullery L.L., Gibbs J.P., Ames G.W., Senecal F.M., Slattery J.T. Busulfan clearance in renal failure and hemodialysis. Bone Marrow Transplant 2000, 25:201-203.
23. Jacobson P.A., Green K., Birnbaum A., Remmel R.P. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002, 49:461-467.
24. Egger S.S., Meier S., Leu C., et al. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant 2010, 45:1197-1203.
25. Bolwell B., Sobecks R., Pohlman B., et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004, 34:621-625.
26. Nieto Y., Patton N., Hawkins T., et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 2006, 12:217-225.
27. Furlong T., Martin P., Flowers M.E., et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009, 44:739-748.
28. Zager R.A., O'Quigley J., Zager B.K., et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989, 13:210-216.
29. Hsieh M.M., Kang E.M., Fitzhugh C.D., et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009, 361:2309-2317.
30. Horwitz M.E., Spasojevic I., Morris A., et al. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. Biol Blood Marrow Transplant 2007, 13:1422-1426.
31. Hamaki T., Katori H., Kami M., et al. Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis. Bone Marrow Transplant 2002, 30:195-198.
32. Heitink-Polle K.M., Lilien M.R., Bierings M.B. Successful bone marrow transplantation in a girl with Fanconi anemia and preterminal renal failure. Bone Marrow Transplant 2008, 42:57-58.
33. Turkistani W., Ashour M., Al-Mojalli H., Ayas M. Successful allo-SCT in a Fanconi anemia patient with renal impairment using reduced doses of CY and fludarabine. Bone Marrow Transplant 2010, 45:415-416.
34. Miano M., Ginevri F., Nocera A., et al. Successful double bone marrow and renal transplantation in a patient with Fanconi anemia. Blood 2002, 99:3482-3483.
35. Kersting S., Verdonck L.F. Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction. Biol Blood Marrow Transplant 2008, 14:1312-1316.
36. de Souza J.A., Saliba R.M., Patah P., et al. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:1094-1099.
37. Massenkeil G., Roigas J., Nagy M., et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 2004, 34:309-316.
38. Bregni M., Bernardi M., Servida P., et al. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplant 2009, 44:237-242.
39. Termuhlen A.M., Grovas A., Klopfenstein K., Rosselet R., Gross T.G. Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate. Pediatr Transplant 2006, 10:830-834.
40. Bischoff M.E., Blau W., Wagner T., et al. Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis. Bone Marrow Transplant 1998, 22:591-593.
41. Ballester O.F., Tummala R., Janssen W.E., et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997, 20:653-656.
42. Gertz M.A., Leung N., Lacy M.Q., Dispenzieri A. Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. Kidney Int 2005, 68:1464-1471.
43. Knudsen L.M., Nielsen B., Gimsing P., Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005, 75:27-33.
44. Casserly L.F., Fadia A., Sanchorawala V., et al. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003, 63:1051-1057.
45. Royer B., Arnulf B., Martinez F., et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004, 65:642-648.
46. Barlogie B., Shaughnessy J., Tricot G., et al. Treatment of multiple myeloma. Blood 2004, 103:20-32.
47. Gahrton G., Svensson H., Cavo M., et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001, 113:209-216.
48. Bjorkstrand B.B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996, 88:4711-4718.
49. Sharabi Y., Sachs D.H. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989, 169:493-502.
50. Kawai T., Cosimi A.B., Colvin R.B., et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995, 59:256-262.
51. Sykes M., Szot G.L., Swenson K.A., Pearson D.A. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997, 3:783-787.
52. Sykes M., Preffer F., McAfee S., et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999, 353:1755-1759.
53. Spitzer T.R., McAfee S., Sackstein R., et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000, 6:309-320.
54. Spitzer T.R., Delmonico F., Tolkoff-Rubin N., et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999, 68:480-484.
55. Fudaba Y., Spitzer T.R., Shaffer J., et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 2006, 6:2121-2133.
56. Spitzer T.R., Sykes M., Tolkoff-Rubin N., et al. Long-term follow-up of recipients of combined HLA-matched nonmyeloablative bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Blood 2009, 114:1307-1308.
57. Kawai T., Cosimi A.B., Spitzer T.R., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008, 358:353-361.
58. Dey B., Sykes M., Spitzer T.R. Outcomes of recipients of both bone marrow and solid organ transplants. A review. Medicine (Baltimore) 1998, 77:355-369.
59. Barraclough K.A., Robinson K.L., Dowling J.P., Schwarer A.P., Perry G.J. Renal graft rejection after allogeneic peripheral-blood stem cell transplantation. Am J Kidney Dis 2006, 48:822-826.
60. Leung N., Gloor J.M., Dean P.G., Lacy M.Q., Porrata L.F., Griffin M.D. Acute cellular rejection in a renal allograft immediately following leukocyte engraftment after auto-SCT. Bone Marrow Transplant 2009, 43:345-346.